Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Defective in cullin neddylation 1 domain containing 5 (DCUN1D5) encodes a protein that is a member of the DCUN1/NEDD8 E3 ligase family, which facilitates neddylation—the covalent attachment of NEDD8 (a ubiquitin-like protein) to target cullin proteins[1][4]. This neddylation is crucial for activating cullin-RING E3 ubiquitin ligases, key regulators of protein degradation, cell cycle progression, and various cellular responses[1][8][10]. DCUN1D5 has been implicated in cell proliferation, DNA damage response, and anchorage-independent cell growth, and may play a role in cancer biology by influencing cullin-dependent protein turnover[1][4][9]. It primarily localizes to the nucleus and mitotic spindle[1][5]. There are no known approved drugs that directly target DCUN1D5, and it is not currently established as a principal drug target, but it may represent a potential vulnerability in cancer (as suggested by alternative names such as "squamous cell carcinoma-related oncogene 5")[1][4]. Note: While DCUN1D5 is a significant regulator in ubiquitin-proteasome system modulation and cancer biology, there are currently no direct pharmacologic inhibitors or clinical trials targeting this protein. It is a protein coding gene with growing importance in cancer research, but not a typical therapeutic target like a receptor, enzyme, or transporter[1][4][9].
Modulation of neddylation and cullin-RING E3 ubiquitin ligase activity
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Defective in cullin neddylation 1 domain containing 5 (DCUN1D5).